Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus chemotherapy in platinum-resistant recurrent ovarian cancer
ChiCTR-OPN-17011652Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Jun 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Rivoceranib in ovarian cancer (2 arms), sponsored by Xijing Hospital. Primary endpoint: progression-free survival. Planned start Jun 2017; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR-OPN-17011652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-17011652.